Form 4: GoodRx Executive Exercises RSUs, Sells Shares for Tax

GoodRx Director and Officer Wendy Lynn Barnes reported the exercise of restricted stock units and subsequent tax-related sales of Class A Common Stock on January 15, 2026.

Summary

• Wendy Lynn Barnes, a Director and Officer of GoodRx Holdings, Inc., reported transactions involving Class A Common Stock.
• On January 15, 2026, Barnes acquired 460,594 shares of Class A Common Stock through the exercise of restricted stock units (RSUs).
• Concurrently, 148,383 shares were disposed of at a price of $2.75 per share to cover tax obligations related to the RSU vesting.
• Barnes also acquired an additional 204,708 shares of Class A Common Stock from another RSU award on the same date.
• An additional 88,926 shares were disposed of at $2.75 per share for tax withholding purposes related to this second RSU vesting.
• Following these transactions, Barnes beneficially owns 312,211 shares and 427,993 shares from the respective transactions, totaling 740,204 shares of Class A Common Stock directly.
• The first RSU award (460,594 shares) vests 25% on January 15, 2026, with the remaining 75% vesting in approximately equal quarterly installments over 12 quarters.
• The second RSU award (204,708 shares) vests 50% on January 15, 2026, with the remaining 50% vesting in approximately equal quarterly installments over 4 quarters.
• Barnes also holds 1,381,780 derivative securities (RSUs) from the first award and 204,708 derivative securities (RSUs) from the second award after these transactions.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax-related sales). These are standard events and do not indicate a positive or negative shift in company fundamentals or outlook.

Positives

• The vesting of restricted stock units indicates the achievement of performance or time-based milestones, aligning executive incentives with shareholder value.
• The exercise of RSUs increases the direct ownership of Class A Common Stock by a key executive.

Negatives

• A portion of the vested shares was sold to cover tax liabilities, which is a common practice but reduces the executive's direct shareholding.

Future Outlook

The filing indicates future vesting events for the remaining restricted stock units. The first RSU award will continue to vest in approximately equal quarterly installments for 12 quarters after January 15, 2026. The second RSU award will vest in approximately equal quarterly installments for 4 quarters after January 15, 2026.

Industry Context

This Form 4 filing details a routine insider transaction involving the vesting and exercise of restricted stock units and subsequent tax-related sales. Such transactions are common across all industries for executives receiving equity compensation and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor impact. Routine insider transactions typically do not significantly affect shareholder value or perception. The executive's continued ownership of a substantial number of shares and RSUs indicates ongoing alignment with shareholder interests.

Next Steps

• Continued vesting of the remaining 75% of the first RSU award in approximately equal quarterly installments over 12 quarters following January 15, 2026.
• Continued vesting of the remaining 50% of the second RSU award in approximately equal quarterly installments over 4 quarters following January 15, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting and tax-related sale of restricted stock units. Such events are standard and do not provide new fundamental information about GoodRx Holdings, Inc. that would warrant a change in investment recommendation. Investors should consider broader company performance, market conditions, and strategic outlook rather than these routine disclosures for investment decisions.

Keywords

GoodRx, GDRX, Form 4, insider transaction, restricted stock units, RSU vesting, executive compensation, stock sale, tax withholding